Preprint record
The most critical step during viral infection is when viruses enter the cell. A novel coronavirus SARS CoV 2 penetrates into alveolar cells through the transmembrane serine protease TMPRSS2. Extensive studies show that a clinically approved drug from Japan and South Korea, camostat mesylate inactivates TMPRSS2 in order to prevent the infection. However, these basic studies have not been translated to “bedside”, and their effectiveness has not been clinically confirmed yet. Here, we describe another potential antiviral substance, commonly used in the clinical practice as a mucolytics bromhexine hydrochloride. Causing only few mild side effects, it may serve as either a new therapeutic strategy during early stages of the disease or a preventive agent blocking SARS CoV 2 entry into alveolar cells through TMPRSS2. Therefore, in this review, we discuss these possible approaches based on the current data.
Dmitry Stepanov and Peter Lierz (April 23, 2020). Bromhexine Hydrochloride: Potential Approach to Prevent or Treat Early Stage COVID 19. Frenxiv. https://doi.org/10.31226/osf.io/j4ut2
This record is deposited on the Open Science Framework and carries a persistent DOI. Use the links below to locate it in scholarly indexes.
Frenxiv records connect to the wider scholarly record. These services support discovery, identifiers, preservation and open licensing.